Biofidelity, a private company founded in 2019 in Cambridge, UK, is revolutionising access to best-in-class cancer diagnostics, breaking down the barriers to better screening, monitoring and treatment for all cancer patients.  

Our disruptive diagnostic technology platform provides comprehensive panels of clinically actionable data based on ultra-sensitive detection of the markers recommended in cancer treatment guidelines, enabling all patients to be prescribed the right drug at the right time. Biofidelity is developing panels for non-small cell lung and colorectal cancer, with potential in a broad range of cancers as well as in the detection of resistance to therapy and disease recurrence.